Fauci: Chances of CCP Virus Vaccine Being Highly Effective Are ‘Not Great’
The prospect of scientists developing a highly effective CCP (Chinese Communist Party) virus vaccine is “not great,” according to Dr. Anthony Fauci. Fauci, the head of the National Institute of Allergy and Infectious Diseases, is a top infectious disease expert. Speaking about the vaccine in a discussion with the Brown University School of Public Health, Fauci said Friday, “The chances of it being 98 percent effective is not great, which means you must never abandon the public health approach.” Vaccine effectiveness refers to the percentage of people given vaccines who are actually protected from infection. As of now, it’s unclear whether CCP virus vaccines will even protect one out of every two people that get them, according to Fauci. “We don’t know yet what the efficacy might be,” he said, but added,…
Chinese companies listed on U.S. stock exchanges have a combined market capitalization of over half a trillion dollars. But they don’t comply with American financial regulations, because Beijing restricts access to full audits.
Congressional members on both sides of the aisle have demanded more transparency, and the Trump administration has made moves to stop U.S. pension funds from investing in Chinese firms.
So where is the U.S.-China relationship headed? Will the U.S. decouple completely?
And why does it look like the Chinese leadership is getting nervous about their ability to maintain power?
In this episode, we sit down with former congressman Dave Brat, dean of the Liberty University School of Business.
This is American Thought Leaders ??, and I’m Jan Jekielek.
American Thought Leaders is an Epoch Times show available on YouTube, Facebook, and The Epoch Times website. It airs on Verizon Fios TV and Frontier Fios on Channel 158 every Tuesday and Thursday at 7:30pm ET and Saturday at 10:30am ET.
Focus News: Why the U.S. Should Decouple from China: Dave Brat
Jeffrey Epstein’s Alleged Victims Get Chance to Challenge Plea Deal, Appeal Court Rules
Alleged victims of deceased convicted sex-trafficker Jeffrey Epstein will have a chance to challenge a federal non-prosecution agreement—often referred to as Epstein’s “sweetheart” plea deal—that was signed more than a decade ago. Courtney Wild, an Epstein accuser originally known as Jane Doe 1, as well as another plaintiff known as Jane Doe 2, had filed an original lawsuit in 2008 to overturn the non-prosecution agreement. They argued that the Department of Justice (DOJ) prosecutors had violated their rights under the 2004 Crime Victims’ Rights Act (CRVA) by sealing the deal without consulting with or informing the alleged victims. The Atlanta-based U.S. Court of Appeals for the 11th Circuit court ruled on Friday (pdf) that the alleged victims will have their case reheard en banc—a legal term to mean that a case gets to…